For NSCLC patients treated with neoadjuvant chemoimmunotherapy and surgery with ypN2 disease, what factors would cause you to recommend PORT?  

This question is a tough one, and the multidisciplinary teams I work with are still trying to figure it out. This is mostly because only 13% (67/501) of randomized participants in the Lung ART study received neoadjuvant chemotherapy, and 0% received neoadjuvant chemoimmunotherapy; all had pN2 or ypN...

Agree with Dr. @Moghanaki that this is a tough question.I have recommended PORT less and less often since the publication of Lung ART. However, there are a few indications where I think postoperative RT still makes good oncologic sense after neoadjuvant chemoimmunotherapy and surgery. One situa...